BB Biotech AG operates in the Investors sector.
In addition to historical fundamental analyses, the complete report available to purchase compares BB Biotech AG with three other
financial institutions in Europe:
sales of 218.92 million Euros [US$240.04 million]
HBM Healthcare Investments AG
(215.50 million Swiss Francs [US$223.09 million]
Aforti Holding SA
based in POLAND
(1.04 billion Polish New Zlotys [US$246.86 million]
BB Biotech AG reported sales of 240.87 million Swiss Francs (US$249.35 million)
December of 2019.
increase of 59.5%
versus 2018, when the company's sales were 150.99 million Swiss Francs.
Despite this increase, sales are still
below the level achieved in 2017, when BB Biotech AG
reported sales of 270.33 million Swiss Francs.
The sales level in 2019 was fairly close to the level five years ago: in 2014, BB Biotech AG had sales
of 222.15 million Swiss Francs.